LifeMD, Inc. (NASDAQ:LFMD) Stake Raised by Barclays PLC

Barclays PLC lifted its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD) by 311.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 49,017 shares of the company’s stock after buying an additional 37,112 shares during the period. Barclays PLC owned approximately 0.11% of LifeMD worth $257,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. State Street Corp boosted its position in LifeMD by 20.0% during the 3rd quarter. State Street Corp now owns 1,155,495 shares of the company’s stock worth $6,055,000 after acquiring an additional 192,861 shares during the period. Los Angeles Capital Management LLC raised its stake in shares of LifeMD by 852.6% during the third quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock valued at $637,000 after purchasing an additional 108,822 shares in the last quarter. Geode Capital Management LLC lifted its holdings in LifeMD by 11.4% in the third quarter. Geode Capital Management LLC now owns 819,233 shares of the company’s stock worth $4,293,000 after purchasing an additional 83,598 shares during the period. The Manufacturers Life Insurance Company bought a new position in LifeMD in the 2nd quarter valued at about $93,000. Finally, Centiva Capital LP acquired a new position in LifeMD during the 3rd quarter valued at about $196,000. 35.52% of the stock is owned by institutional investors.

LifeMD Stock Performance

LifeMD stock opened at $4.90 on Tuesday. The firm has a market capitalization of $212.22 million, a price-to-earnings ratio of -7.66 and a beta of 1.49. The company has a 50 day moving average price of $5.54 and a 200 day moving average price of $5.44. LifeMD, Inc. has a 52 week low of $3.99 and a 52 week high of $12.88.

Analysts Set New Price Targets

A number of research analysts recently commented on LFMD shares. Lake Street Capital began coverage on shares of LifeMD in a research note on Tuesday, December 10th. They set a “buy” rating and a $12.00 price objective on the stock. Mizuho started coverage on shares of LifeMD in a research report on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 price target on the stock. KeyCorp cut their price target on shares of LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of LifeMD in a report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.14.

Insider Buying and Selling

In other LifeMD news, CEO Justin Schreiber sold 25,000 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $5.19, for a total value of $129,750.00. Following the transaction, the chief executive officer now directly owns 2,703,715 shares of the company’s stock, valued at $14,032,280.85. This represents a 0.92 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 15.97% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.